Raymond James downgraded HCA Healthcare (HCA) to Market Perform from Outperform without a price target The firm expects a reduction in the Affordable Care Act exchange population in 2026 “due to the sunsetting of enhanced subsidies.” There is growing investor concerns about a number of other risks, including the explosive growth in state-directed payments, risks to Medicaid and the potential re-emergence of the site neutral debate, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare exec Whalen sells 1,474 common shares
- HCA Healthcare price target lowered to $392 from $396 at Barclays
- HCA Healthcare price target raised to $400 from $395 at Wells Fargo
- HCA Healthcare price target raised to $400 from $390 at Oppenheimer
- HCA Healthcare price target lowered to $440 from $450 at TD Cowen